P21 peptide (P021): what the animal studies show and why there is no human evidence

The P21 peptide is the vendor name for Peptide 021, usually written P021 in the scientific literature. It comes from a research programme led by Khalid Iqbal and the late Inge Grundke-Iqbal at the New York State Institute for Basic Research in Developmental Disabilities. Their idea was that ciliary neurotrophic factor (CNTF), a natural growth factor that supports neurons, could not be used as a drug because it causes anorexia, muscle loss, cramps and pain, but that a small piece of it might keep the useful activity without the side effects. In 2011 the group reported Peptide 6, an 11-amino-acid fragment based on an active region of CNTF, which increased neurogenesis in the dentate gyrus of the hippocampus and improved memory in mice when delivered by a slow-release pellet under the skin ^[1].

The group then mapped which part of Peptide 6 mattered and found that a four-residue stretch, Asp-Gly-Gly-Leu, corresponding to CNTF residues 147 to 150, was enough. In 2010 they published this tetrapeptide as Peptide 6c and showed that it too enhanced neurogenesis and spatial memory in mice without weight loss ^[2]. To make the tetrapeptide druggable, an adamantylated glycine was added at its C-terminal end to increase blood-brain barrier permeability and slow its degradation by exopeptidases; that modified compound is P021 ^[3]. Adamantane is the cage-like hydrocarbon found in the drugs amantadine and memantine, and it is the same modification that vendors claim for Adamax.

P021 is described in the papers as a neurotrophic peptidergic compound or a CNTF small-molecule peptide mimetic, and its molecular weight of about 579 g/mol puts it at the boundary between a peptide and a small-molecule drug. It is sold by research peptide stores as a P21 nootropic and neuroprotective agent, usually in freeze-dried vials, and is often listed with Semax, Selank and Dihexa. PepFinder lists only vials.

The proposed mechanism has two parts. First, Peptide 6 and its derivatives act by competitively inhibiting signalling through the leukaemia inhibitory factor (LIF) pathway, which in the adult brain restrains the maturation of new neurons; blocking it is proposed to tip neural progenitor cells towards becoming neurons ^[1]. Second, the peptides increase expression of brain-derived neurotrophic factor (BDNF), a protein central to synapse formation and memory, and downstream markers of synaptic plasticity such as synaptophysin, PSD-95 and MAP2 ^{[1] [4]}. The developers’ 2016 review summarises P021 as a neurogenic and neurotrophic compound that enhances dentate gyrus neurogenesis and memory by inhibiting LIF signalling and increasing BDNF expression ^[5].

Whether the same holds for P21 in every setting is not certain. In the most recent study, from an independent group in Bologna, chronic P021 treatment in mice lacking the CDKL5 gene unexpectedly failed to increase BDNF levels and did not improve the animals’ brain abnormalities, even though the peptide worked as expected in cultured human cells ^[6]. That is a reminder that a mechanism established in one model does not automatically transfer.

The P021 literature is unusually consistent in its findings, and unusually concentrated in one institute. Almost every efficacy paper has Khalid Iqbal as senior author, and he holds US patents on CNTF small-molecule peptide mimetics for the treatment of Alzheimer’s disease and related conditions, a conflict of interest the papers declare ^[7]. The results are summarised here by model.

Cognitive ageing: in 22- to 24-month-old Fischer rats, chronic oral P021 significantly reduced the age-related decline in learning and memory, inhibited the age-related deficit in neurogenesis, increased BDNF expression, restored synaptic deficits in cortex and hippocampus, and lowered hippocampal myo-inositol, a metabolite raised in aged brain, on MRI spectroscopy ^[4].

Alzheimer’s-model mice: in 3xTg-AD mice, which develop both amyloid plaques and tau tangles, chronic oral P021 in the diet had what the authors called a disease-modifying effect, improving cognition and reducing tau and amyloid pathology ^[8]. When P021 was started at 3 months, before any overt pathology, and continued to 21 months, it prevented dendritic and synaptic deficits, boosted neurogenesis and reversed cognitive impairment ^[3]. Given only from prenatal day 8 to postnatal day 21, it still rescued cognitive deficits at 4 months and reduced tau and amyloid pathology at 22 months ^[9], and a follow-up study reported similar prevention when treatment began in early postnatal life ^[10]. An earlier study of the parent Peptide 6 in 3xTg-AD mice had reversed neurogenic and plasticity deficits and cognitive impairment without affecting amyloid or tau ^[11].

Sporadic Alzheimer’s model: in rats engineered to express fragments of the phosphatase inhibitor SET, which reproduces tau hyperphosphorylation and memory loss without a genetic mutation, 40 days of Peptide 6 rescued neurodegeneration and cognitive deficit and increased synaptic markers in the hippocampus ^[12].

Down syndrome: in Ts65Dn mice, a model of trisomy 21, Peptide 6 rescued synaptic failure and improved learning and memory ^[13], and prenatal to early postnatal P021 rescued developmental delay in pups and Alzheimer’s-like memory impairment in adult life, while reducing GSK-3β activity and raising BDNF ^[7].

Autism model: sera from children with autism injected into newborn rats produced developmental delay and social deficits, and Peptide 6 treatment ameliorated both the brain changes and the behaviour ^[14]. This is a proof-of-principle study in an unusual model rather than evidence about autism treatment.

Comparison with Cerebrolysin: a 2011 study from a separate group in San Diego compared CNTF-derived peptides with Cerebrolysin, a licensed porcine brain peptide mixture, in amyloid-precursor-protein transgenic mice and reported regional differences in their neurogenic effects ^[15]. It is the only head-to-head comparison of this peptide family with a marketed product.

CDKL5 deficiency disorder: the 2024 Bologna study found that P021 restored neuronal proliferation, survival and maturation in a human cell model of this severe epileptic encephalopathy, but chronic treatment of Cdkl5 knockout mice did not raise BDNF or correct brain defects and gave only limited behavioural benefit ^[6]. This is the only independent in vivo test of P021 we found, and it was largely negative.

There are none. We found no published human study of P021 or Peptide 6, no pharmacokinetic study in people and no clinical trial registered on ClinicalTrials.gov as of September 2026. The developers’ 2016 review describes P021 as a candidate for clinical development ^[5], but a decade later no trial has been reported. Everything a buyer reads about P21 memory, neurogenesis or Alzheimer’s benefits is an extrapolation from rodents.

So does P21 work? In mice and rats, in the hands of the developers, consistently yes across ageing, Alzheimer’s and Down syndrome models. In the one independent animal study, mostly no. In humans, the question has not been tested.

The animal studies all used chronic dosing. Peptide 6 was delivered for 30 days from a subcutaneous slow-release pellet ^{[1] [2]} and for 40 days by peripheral injection in the rat model ^[12]; P021 was given in the diet for months, and in the prevention studies for up to 18 months ^{[3] [8]}. The effects measured, new neuron formation and synapse growth, are slow biological processes, and none of the studies reported an acute effect on behaviour. Claims that P21 is felt within hours have no basis in the published work, and no human timeline exists.

These are animal doses, reported because people search for them; they are not recommendations and cannot be converted to a human dose. Peptide 6 was given by subcutaneous extended-release pellets over 30 days in mice ^{[1] [2]} and by peripheral injection for 40 days in rats ^[12]. P021 was mixed into the animals’ diet in most studies, with treatment lasting from weeks to 18 months ^{[3] [8] [9]}. The abstracts do not report a milligram-per-kilogram figure, and the diet-based studies imply continuous low-level exposure rather than the intermittent injections sold online.

Vendor P21 dosing charts quoting a daily subcutaneous or nasal amount in micrograms or milligrams are not drawn from these papers. Our peptide calculator and the P21 calculator page convert vial contents into concentrations for record-keeping; they do not imply a dose.

In the research, P021 was given orally in food and its parent peptides were injected or implanted under the skin ^{[1] [3] [8]}. The adamantyl modification was added specifically so the compound could be taken by mouth and reach the brain ^[3]. We found no study of P021 as a P21 nasal spray, which is one of the forms sold. Vendors sell it as a freeze-dried powder for reconstitution with bacteriostatic water, and sometimes pre-mixed as a spray; PepFinder lists only vials.

There are no human safety data. In animals, the reason the peptides were made in the first place was to avoid CNTF’s side effects, and the papers report that Peptide 6c improved cognition without weight loss or any other apparent side effects in mice ^[2]. Long-term dietary P021 for up to 18 months in mice was not reported to cause harm ^[3], and prenatal exposure did not produce reported developmental toxicity ^[9]. These are efficacy studies that were not designed as toxicology, and the absence of reported harm is not the same as demonstrated safety.

Two theoretical concerns follow from the mechanism. Growth factor mimetics that promote cell proliferation raise the question of effects on abnormal cell growth, which no study has examined for P021. And the LIF pathway that P021 is proposed to inhibit has roles outside the brain, including in immune signalling, the heart and implantation in pregnancy; the mouse studies that dosed through pregnancy ^{[7] [9]} did not report problems, but they were not designed to detect them.

P21 is sold as an unregulated research chemical. Our guides to spotting a fake peptide supplier and what research peptides are apply.

P21 is usually compared with other nootropic peptides. Semax has a Russian registration and small human studies, which P21 lacks; on the other hand, P21 has a larger and more consistent body of animal work on neurogenesis than Semax. Dihexa has animal data too, but its mechanism papers were retracted in 2025 and it has no independent replication beyond one mouse study, whereas P21 has one independent test, which was largely negative. Cerebrolysin is a licensed medicine in some countries with human trials, and the only direct comparison with the CNTF peptides is a 2011 mouse study ^[15]. None of the four has a controlled human trial showing cognitive benefit in healthy people. Our Semax vs Selank comparison covers the two Russian peptides.

P21 is not an approved medicine in any country and has never been in a clinical trial. It is not on the US FDA’s list of compounding bulk substances that were nominated and withdrawn, nor in its category 2 list, so it has no compounding status; it is an unapproved research chemical. The underlying patents are held by the New York State Institute for Basic Research, which does not affect a buyer but means no licensed product exists. See our legal status overview, including the UK, US and Australian pages.

P021 was designed to resist breakdown by exopeptidases ^[3], but no shelf-life data for the powder or reconstituted solution have been published. Keep it cold, dry and away from light, refrigerate solutions and use them within a limited period. See our peptide storage guide.

P21 is a short modified peptide, which is easy to synthesise but also easy to substitute with an unmodified tetrapeptide that would lack the adamantyl group. A certificate of analysis should show a measured mass close to 579 g/mol, which distinguishes P021 from the plain tetrapeptide, and an HPLC purity figure; see how to read a peptide COA and our guide to third-party peptide testing.

You can compare P21 prices, including P21 in the UK, in the US and in Canada, and see our list of third-party tested suppliers. A listing is not a statement that a product is legal to buy or appropriate to use.